Original Article
Prognostic significance of DNA damage response-related markers in esophageal squamous cell carcinoma using machine learning approaches
Journal of Gastrointestinal Oncology
2026;
17
(4)
:204
.
(31 August 2026)
The association between coffee consumption and esophageal cancer risk: a systematic review and meta-analysis of current observational evidence
Journal of Gastrointestinal Oncology
2026;
17
(4)
:205
.
(31 August 2026)
FANCI promotes esophageal squamous cell carcinoma progression and cell cycle regulation and interacts with FANCD2
Journal of Gastrointestinal Oncology
2026;
17
(4)
:206
.
(31 August 2026)
Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:207
.
(31 August 2026)
Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis
Journal of Gastrointestinal Oncology
2026;
17
(4)
:208
.
(31 August 2026)
Prediction-model development and temporal validation for six-month cancer-specific mortality in de novo metastatic gastroesophageal junction adenocarcinoma: a SEER-based study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:209
.
(31 August 2026)
Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:210
.
(31 August 2026)
Nodal status and advanced clinical stage as determinants of response and survival after induction chemoradiotherapy in esophageal and gastroesophageal junction cancer: a single-centre retrospective cohort study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:211
.
(31 August 2026)
Screening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma
Journal of Gastrointestinal Oncology
2026;
17
(4)
:212
.
(31 August 2026)
Non-structural maintenance of chromosome condensin I complex subunit H knockdown suppresses malignant progression of esophageal squamous cell carcinoma via the Wnt/β-catenin signaling pathway
Journal of Gastrointestinal Oncology
2026;
17
(4)
:213
.
(31 August 2026)
The prognosis of patients with gastrointestinal stromal tumors harboring the KIT exon 11 mutation: a retrospective cohort study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:214
.
(31 August 2026)
Cuproplasia-associated LOXL2 cooperates with Helicobacter pylori infection to promote gastric cancer progression via the FAK/Src signaling axis
Journal of Gastrointestinal Oncology
2026;
17
(4)
:215
.
(31 August 2026)
Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:216
.
(31 August 2026)
Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM
Journal of Gastrointestinal Oncology
2026;
17
(4)
:217
.
(31 August 2026)
Helicobacter pylori-induced cystathionine-γ-lyase drives redox imbalance and metabolic remodeling in gastric cancer
Journal of Gastrointestinal Oncology
2026;
17
(4)
:218
.
(31 August 2026)
Development of a postoperative risk scoring tool for elderly patients with early gastric cancer: an exploratory prognostic score derivation study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:219
.
(31 August 2026)
Increased expression of Ribonucleic acid export 1 (RAE1) gene promotes gastric carcinogenesis and is associated with activation of Hippo signaling pathway
Journal of Gastrointestinal Oncology
2026;
17
(4)
:220
.
(31 August 2026)
Impact of spatial distribution of M2 macrophages on prognosis and neoadjuvant chemotherapy resistance in gastric cancer
Journal of Gastrointestinal Oncology
2026;
17
(4)
:221
.
(31 August 2026)
Distinct metastatic patterns and survival outcomes in intestinal- versus diffuse-type gastric cancer: a SEER-based propensity score-matched analysis
Journal of Gastrointestinal Oncology
2026;
17
(4)
:222
.
(31 August 2026)
Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression
Journal of Gastrointestinal Oncology
2026;
17
(4)
:223
.
(31 August 2026)
A predictive nomogram model for overall survival in obstructive colorectal cancer based on clinical and laboratory indicators
Journal of Gastrointestinal Oncology
2026;
17
(4)
:224
.
(31 August 2026)
Trajectory identification of high-risk subgroups after colorectal cancer surgery in patients with minimal residual disease: a single-center longitudinal study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:225
.
(31 August 2026)
Histopathological subtypes independently predict survival in ampullary carcinoma: a contemporary SEER nomogram study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:226
.
(31 August 2026)
Sphingosine-1-phosphate induces angiogenesis via the activating STAT3 signaling pathway to drive colorectal cancer progression
Journal of Gastrointestinal Oncology
2026;
17
(4)
:227
.
(31 August 2026)
Artemisinin inhibits colorectal cancer progression via the FAM83A-AS1/HIF-1α axis
Journal of Gastrointestinal Oncology
2026;
17
(4)
:228
.
(31 August 2026)
Metabolic-cell-death gene trio predicts survival and cuproptosis sensitivity in colorectal cancer
Journal of Gastrointestinal Oncology
2026;
17
(4)
:229
.
(31 August 2026)
Real-world efficacy and safety of fruquintinib plus PD-1 inhibitors with or without radiotherapy in refractory metastatic colorectal cancer: a single-center retrospective cohort study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:230
.
(31 August 2026)
Association between metabolic dysfunction-associated steatotic liver disease and risk of early-onset advanced colorectal neoplasia: a systematic review and meta-analysis
Journal of Gastrointestinal Oncology
2026;
17
(4)
:231
.
(31 August 2026)
MS4A3 as a potential prognostic biomarker for colon cancer: integrated analysis of expression patterns and immune cell infiltration
Journal of Gastrointestinal Oncology
2026;
17
(4)
:232
.
(31 August 2026)
Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:233
.
(31 August 2026)
Prognostic significance of lymphovascular invasion in colorectal mucinous adenocarcinoma after curative resection: a nationwide multi-center retrospective cohort study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:234
.
(31 August 2026)
A study on screening of postoperative chemotherapy beneficial populations in stage II colorectal cancer based on diffusion weighted imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography
Journal of Gastrointestinal Oncology
2026;
17
(4)
:235
.
(31 August 2026)
Prognostic value of genes associated with metastasis and propionate metabolism in rectal cancer
Journal of Gastrointestinal Oncology
2026;
17
(4)
:236
.
(31 August 2026)
Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
Journal of Gastrointestinal Oncology
2026;
17
(4)
:237
.
(31 August 2026)
Prognostic impact of mucinous adenocarcinoma after curative surgery for stage I–III colorectal cancer: a large population-based cohort study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:238
.
(31 August 2026)
Comparative analysis of outcomes and sociodemographic factors in early- and late-onset colorectal cancer hospitalizations
Journal of Gastrointestinal Oncology
2026;
17
(4)
:239
.
(31 August 2026)
Modifiable risk factors contributing to the rising incidence of early-onset colorectal cancer in the United States over three decades: a Global Burden of Disease analysis
Journal of Gastrointestinal Oncology
2026;
17
(4)
:240
.
(31 August 2026)
Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior
Journal of Gastrointestinal Oncology
2026;
17
(4)
:241
.
(31 August 2026)
Prediction of histological response by PET-CT after 2 weeks of neoadjuvant chemo-radiotherapy for rectal cancer: a prospective clinical trial
Journal of Gastrointestinal Oncology
2026;
17
(4)
:242
.
(31 August 2026)
Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy
Journal of Gastrointestinal Oncology
2026;
17
(4)
:243
.
(31 August 2026)
Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection
Journal of Gastrointestinal Oncology
2026;
17
(4)
:244
.
(31 August 2026)
Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial
Journal of Gastrointestinal Oncology
2026;
17
(4)
:245
.
(31 August 2026)
Application value of dual-phase cone-beam computed tomography during hepatic arteriography in the detection of ≤2 cm hypervascular hepatocellular carcinoma and its feeding arteries
Journal of Gastrointestinal Oncology
2026;
17
(4)
:246
.
(31 August 2026)
Development and validation of a novel nomogram for predicting long-term survival in gallbladder cancer: a large population-based study using the SEER database
Journal of Gastrointestinal Oncology
2026;
17
(4)
:247
.
(31 August 2026)
Development and validation of prognostic nomograms for intrahepatic cholangiocarcinoma with concomitant hepatolithiasis after radical resection
Journal of Gastrointestinal Oncology
2026;
17
(4)
:248
.
(31 August 2026)
Metabolic burden but not metabolic dysfunction-associated steatotic liver disease affects the prognosis of patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:249
.
(31 August 2026)
Global impact of hepatitis B vaccination on the risk of hepatocellular carcinoma: a systematic review and meta-analysis
Journal of Gastrointestinal Oncology
2026;
17
(4)
:250
.
(31 August 2026)
Immunological characteristics of calmodulin-related genes in hepatocellular carcinoma and their potential for prognostic prediction and diagnostic applications
Journal of Gastrointestinal Oncology
2026;
17
(4)
:251
.
(31 August 2026)
Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis
Journal of Gastrointestinal Oncology
2026;
17
(4)
:252
.
(31 August 2026)
Relationships among slow diffusion coefficient and diffusion-derived ‘vessel density’ signal features, Gadoxetate delayed enhancement, tumor size, tumor grading, and patient survival: an exploratory study of mass-forming intrahepatic cholangiocarcinoma
Journal of Gastrointestinal Oncology
2026;
17
(4)
:253
.
(31 August 2026)
Construction of molecular signatures based on the co-expression network of NECSO-related gene TRPM4 and its prognostic value in hepatocellular carcinoma
Journal of Gastrointestinal Oncology
2026;
17
(4)
:254
.
(31 August 2026)
Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:255
.
(31 August 2026)
A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:256
.
(31 August 2026)
SLC25A45 as a prognostic biomarker promotes malignant progression via mutant p53 in hepatocellular carcinoma
Journal of Gastrointestinal Oncology
2026;
17
(4)
:257
.
(31 August 2026)
A novel glutamine metabolism-based classification system for characterizing the heterogeneity of hepatocellular carcinoma
Journal of Gastrointestinal Oncology
2026;
17
(4)
:258
.
(31 August 2026)
A CFH- and SPINT2-based prognostic signature for cholangiocarcinoma
Journal of Gastrointestinal Oncology
2026;
17
(4)
:259
.
(31 August 2026)
Evolving burden of pancreatic cancer in the Middle East and North Africa Region, 1990–2023: an analysis based on the Global Burden of Disease Study 2023
Journal of Gastrointestinal Oncology
2026;
17
(4)
:260
.
(31 August 2026)
Association between preoperative statin use and survival after pylorus-preserving pancreaticoduodenectomy for pancreatic or periampullary cancer: a propensity score-matched cohort study
Journal of Gastrointestinal Oncology
2026;
17
(4)
:261
.
(31 August 2026)
Development and validation of a nomogram based on three-dimensional quantitative parameters from dual-layer detector spectral computed tomography for predicting treatment response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma
Journal of Gastrointestinal Oncology
2026;
17
(4)
:262
.
(31 August 2026)
Review Article
Chronic psychological stress and gastric cancer: bidirectional associations, biological mechanisms, and clinical implications—a narrative review
Journal of Gastrointestinal Oncology
2026;
17
(4)
:263
.
(31 August 2026)
MNAT1 in gastrointestinal cancers: mechanistic insights and therapeutic strategies—a narrative review
Journal of Gastrointestinal Oncology
2026;
17
(4)
:264
.
(31 August 2026)
Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review
Journal of Gastrointestinal Oncology
2026;
17
(4)
:265
.
(31 August 2026)
From clinical insight to trial design: advancing circulating tumor DNA-informed care in pancreatic cancer
Journal of Gastrointestinal Oncology
2026;
17
(4)
:266
.
(31 August 2026)
Study Protocol
Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial
Journal of Gastrointestinal Oncology
2026;
17
(4)
:267
.
(31 August 2026)
Case Report
Neuroendocrine tumors of unknown primary: a case report and review of tumors with gastroenteropancreatic features
Journal of Gastrointestinal Oncology
2026;
17
(4)
:268
.
(31 August 2026)
Brief Report
Diagnostic biopsy-to-treatment interval and risk of recurrence in localized pancreatic ductal adenocarcinoma: every week counts
Journal of Gastrointestinal Oncology
2026;
17
(4)
:269
.
(31 August 2026)
Non-operative management of rectal adenocarcinoma in a safety-net system: a decade of real-world outcomes outside watch-and-wait eligibility
Journal of Gastrointestinal Oncology
2026;
17
(4)
:270
.
(31 August 2026)
Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis
Journal of Gastrointestinal Oncology
2026;
17
(4)
:271
.
(31 August 2026)
Letter to the Editor
Prognostic role of resting heart rate in patients with colorectal cancer
Journal of Gastrointestinal Oncology
2026;
17
(4)
:272
.
(31 August 2026)
DNA-dependent protein kinase inhibition as a radiosensitizer in rectal cancer: toxicity must be evaluated in the context of organ preservation
Journal of Gastrointestinal Oncology
2026;
17
(4)
:273
.
(31 August 2026)
Editorial Commentary
Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma?
Journal of Gastrointestinal Oncology
2026;
17
(4)
:274
.
(31 August 2026)
Optimizing hepatocellular carcinoma screening in the era of metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease: time to lower the alpha-fetoprotein threshold
Journal of Gastrointestinal Oncology
2026;
17
(4)
:275
.
(31 August 2026)
Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting
Journal of Gastrointestinal Oncology
2026;
17
(4)
:276
.
(31 August 2026)
Identifying actionable targets: predicting imatinib nonadherence in patients with gastrointestinal stromal tumors
Journal of Gastrointestinal Oncology
2026;
17
(4)
:277
.
(31 August 2026)
Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash
Journal of Gastrointestinal Oncology
2026;
17
(4)
:278
.
(31 August 2026)
Endoscopic ultrasonography ablation for small pancreatic neuroendocrine tumors
Journal of Gastrointestinal Oncology
2026;
17
(4)
:279
.
(31 August 2026)
Editorial
Extending the utility of anti-EGFR therapy in metastatic colorectal cancer
Journal of Gastrointestinal Oncology
2026;
17
(4)
:280
.
(31 August 2026)
Cadonilimab plus chemotherapy in PD-L1-low gastroesophageal cancer: a bispecific opportunity?
Journal of Gastrointestinal Oncology
2026;
17
(4)
:281
.
(31 August 2026)
Ferroptosis in gastrointestinal stromal tumors
Journal of Gastrointestinal Oncology
2026;
17
(4)
:282
.
(31 August 2026)
Erratum
Erratum: Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes
Journal of Gastrointestinal Oncology
2026;
17
(4)
:283
.
(31 August 2026)
